CARL

Business Context and Reporting Period

Company: CARLSMED, INC. (CARL)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2025
Business Overview: Carlsmed is a commercial-stage medical technology company developing the aprevo Technology Platform, an AI-enabled solution for personalized spine fusion surgery. The platform includes surgical planning software and custom-built vertebral interbody implants. The company markets its products to hospitals in the United States via a direct sales team and independent agents.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 98.7% year-over-year for the three months ended June 30, 2025, and 99.4% for the six-month period. This growth was driven by increased surgical procedure volume, with average revenue per procedure remaining substantially flat.
• Operating Expenses: Total operating expenses rose 41.3% (Q2) and 44.5% (YTD) compared to the prior year.
  • Sales & Marketing: Increased 61.5% (Q2) and 72.5% (YTD) due to higher headcount, sales compensation, and independent agent commissions.
  • General & Administrative: Increased 66.3% (Q2) and 64.0% (YTD), driven by professional/legal fees for public company readiness and increased personnel costs.
  • R&D: Remained relatively flat, increasing only 4.1% (Q2) and 0.8% (YTD).
• Net Loss: Net loss increased slightly by 7.8% for the quarter and 6.6% for the six-month period, despite near-doubling of revenue, due to the significant ramp-up in operating expenses.
• Warrant Liabilities: The change in fair value of warrant liabilities resulted in a non-cash loss of $0.2 million for the quarter and $0.3 million for the six months, an increase from the prior year.

Guidance, Outlook, and Risks

• Recent IPO: On July 24, 2025 (post-period), the company completed its Initial Public Offering (IPO), selling 6.7 million shares at $15.00 per share. Net proceeds were approximately $93.5 million. These proceeds are not reflected in the June 30, 2025 financial statements.
• Liquidity: Management believes existing cash, combined with IPO proceeds and available debt capacity ($7.5 million available to draw immediately), is sufficient to fund operations for at least 12 months.
• Product Expansion: The company received FDA 510(k) clearance for cervical spine fusion surgery in November 2024 and expects to commercialize this indication in 2026. CMS provided New Technology Add-On Payments (NTAP) for cervical procedures effective October 1, 2025.
• Key Risks:
  • Dependence on reimbursement rates from Medicare and commercial payors.
  • Reliance on a limited number of Contract Manufacturing Organizations (CMOs).
  • Continued operating losses and need for additional capital if growth targets are not met.
  • Regulatory risks regarding future product clearances.

Investor Verification Checklist

• Reimbursement Stability: Verify the sustainability of premium reimbursement rates (MS-DRGs and NTAP) for custom implants versus stock implants.
• Debt Covenants: Review the Customers Bank Loan Agreement milestones; $4.4 million of the credit facility is contingent on achieving specific revenue targets.
• CMO Capacity: Assess the company's ability to maintain the 10-day delivery timeline via its Digital Production System (DPS) as volume scales.
• Post-IPO Dilution: Note that the IPO converted all preferred stock to common stock and increased the share count significantly; verify the impact on future earnings per share.
• Stock-Based Compensation: Monitor the acceleration of RSU expense recognition following the IPO, which was previously deferred due to performance conditions.